Status:
COMPLETED
Endomicroscopy in IBD Patients
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Crohn's Disease
Ulcerative Colitis
Eligibility:
All Genders
18-70 years
Brief Summary
The aim of the study is to analyze the mechanism of action of infliximab at the endomicroscopic level and to analyze mucosal healing - i.e. structural and functional changes in the mucosa in IBD patie...
Detailed Description
The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. There is recent evidence that with ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Indication for therapy with infliximab according to the current guidelines.
- Exclusion criteria:
- Inability to provide written informed consent
- Pregnancy or breast-feeding
- Severe uncontrolled coagulopathy
- Impaired renal function
- Known allergy to fluorescein
Exclusion
Key Trial Info
Start Date :
May 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01417728
Start Date
May 1 2011
End Date
August 1 2013
Last Update
December 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine I, University of Erlangen-Nuremberg
Erlangen, Germany, 91054